Healthcare

• Cardio products are carrying the company's growth.

• Study progress and spending remain key items to watch.

Cochlear Limited (ASX:COH) reported a FY26 gross margin of 71%, compared with 74% in the preceding year. The three-percentage-point decline indicates that the cost of generating revenue absorbed a greater share of sales. Margin movements can reflect product mix,Manufacturingand supply-chain factors, although the figures …

For the year ended 30 June 2026, CSL reported revenue of approximately USD 15.8 billion, down 1%. Underlying net profit after tax and amortisation, or NPATA, was approximately USD 3.1 billion, down 2%. Reported net profit after tax was a loss of approximately USD …

Ansell Limited (ASX:ANN) reported FY26 sales of USD 2,140.2 million, an increase of 6.8%, with organic constant-currency growth of 5.0%. Adjusted EBIT rose 14.1% to USD 321.9 million, taking the adjusted EBITMarginto 15.0% from 14.1%. Adjusted net profit after tax increased 15.8% to USD …

For FY26, 4DMedical Limited (ASX:4DX) reported operating revenue growth of 21% to $7.1 million, with gross margins above 90%. Software-as-a-service revenue increased 23%. The company associated revenue activity with hospital and radiology relationships, distributors and medical technology partners. Revenue growth indicates greater sales activity, …

Cochlear designs and sells implantable hearing solutions, including cochlear implants, bone conduction implants and acoustic devices, and supports recipients through sound processors, upgrades and services. Revenue falls into three main groups.